Cao Junguo, Yan Weijia, Zhan Zhixin, Hong Xinyu, Yan Hong
Shaanxi Eye Hospital (Xi'an People's Hospital), Affiliated Xi'an Fourth Hospital, Northwestern Polytechnical University; Affiliated Guangren Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Division of Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany.
Front Oncol. 2023 Mar 1;13:1079597. doi: 10.3389/fonc.2023.1079597. eCollection 2023.
Understanding the epidemiology and prognostic factors of low-grade gliomas (LGGs) can help estimate the public health impact and optimize risk stratification and treatment strategies.
3 337 patients diagnosed with LGGs were collected from the Surveillance, Epidemiology, and End Results (SEER) dataset, 2004-2019. The incidence trends of LGGs were analyzed by patient demographics (sex, age, race, and ethnicity). In addition, a competing risk regression model was used to explore the prognostic factors of LGGs by patient demographics, tumor characteristics (histological subtypes, invasiveness, and size), treatment modality, and molecular markers (IDH mutation and 1p/19q codeletion).
LGGs occurred more frequently in male, non-Hispanic, and White populations. The incidence rate of mixed gliomas was stable from 2004 to 2013 and decreased dramatically to nearly zero until 2019. The risk of death increased 1.99 times for every 20-year increase in patient age, and 60 years is a predictive cut-off age for risk stratification of LGGs. Male patients showed poorer LGG-specific survival. Among the different subtypes, astrocytoma has the worst prognosis, followed by mixed glioma and oligodendroglioma. Tumors with larger size (≥5 cm) and invasive behavior tended to have poorer survival. Patients who underwent gross total resection had better survival rates than those who underwent subtotal resection. Among the different treatment modalities, surgery alone had the best survival, followed by surgery + radiotherapy + chemotherapy, but chemotherapy alone had a higher death risk than no treatment. Furthermore, age, invasiveness, and molecular markers were the most robust prognostic factors.
This study reviewed the incidence trends and identified several prognostic factors that help clinicians identify high-risk patients and determine the need for postoperative treatment according to guidelines.
了解低级别胶质瘤(LGGs)的流行病学和预后因素有助于评估其对公众健康的影响,并优化风险分层和治疗策略。
从监测、流行病学和最终结果(SEER)数据集收集了2004年至2019年诊断为LGGs的3337例患者。通过患者人口统计学特征(性别、年龄、种族和民族)分析LGGs的发病率趋势。此外,使用竞争风险回归模型,通过患者人口统计学特征、肿瘤特征(组织学亚型、侵袭性和大小)、治疗方式和分子标志物(异柠檬酸脱氢酶(IDH)突变和1p/19q共缺失)来探索LGGs的预后因素。
LGGs在男性、非西班牙裔和白人人群中更常见。混合性胶质瘤的发病率在2004年至2013年保持稳定,到2019年急剧下降至几乎为零。患者年龄每增加20岁,死亡风险增加1.99倍,60岁是LGGs风险分层的预测临界年龄。男性患者的LGG特异性生存率较差。在不同亚型中,星形细胞瘤的预后最差,其次是混合性胶质瘤和少突胶质细胞瘤。肿瘤较大(≥5 cm)且具有侵袭性行为的患者往往生存率较差。接受全切除的患者生存率高于接受次全切除的患者。在不同的治疗方式中,单纯手术的生存率最佳,其次是手术+放疗+化疗,但单纯化疗的死亡风险高于未治疗。此外,年龄、侵袭性和分子标志物是最有力的预后因素。
本研究回顾了发病率趋势,并确定了几个预后因素,有助于临床医生识别高危患者,并根据指南确定术后治疗的必要性。